nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

19.08.2020 | Original Article

2-[¹⁸F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma

verfasst von: Yanyan Zhao, Caixia Wu, Wei Li, Xueqi Chen, Ziao Li, Xuhe Liao, Yonggang Cui, Guangyu Zhao, Meng Liu, Zhanli Fu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the potential parameters from preoperative 2-[¹⁸F]FDG PET/CT that might associate with the World Health Organization/the International Society of Urological Pathology (WHO/ISUP) grade in clear cell renal cell carcinoma (ccRCC).

Methods

One hundred twenty-five patients with newly diagnosed ccRCC who underwent 2-[¹⁸F]FDG PET/CT prior to surgery or biopsy were retrospectively reviewed. The metabolic parameters and imaging features obtained from 2-[¹⁸F]FDG PET/CT examinations were analyzed in combination with clinical characteristics. Univariate and multivariate logistic regression analyses were performed to identify the predictive factors of WHO/ISUP grade.

Results

Metabolic parameters of primary tumor maximum standardized uptake value (SUVmax), tumor-to-liver SUV ratio (TLR), and tumor-to-kidney SUV ratio (TKR) were significantly different between any two of the four different WHO/ISUP grades, except those between the WHO/ISUP grade 3 and grade 4. The optimal cutoff values to predict high WHO/ISUP grade for SUVmax, TLR, and TKR were 4.15, 1.63, and 1.59, respectively. TLR (AUC: 0.841) was superior to TKR (AUC: 0.810) in distinguishing high and low WHO/ISUP grades (P = 0.0042). In univariate analysis, SUVmax, TLR, TKR, primary tumor size, tumor thrombus, distant metastases, and clinical symptoms could discriminate between the high and low WHO/ISUP grades (P < 0.05). In multivariate analysis, TLR (P < 0.001; OR: 1.732; 95%CI: 1.289–2.328) and tumor thrombus (P < 0.001; OR: 6.199; 95%CI: 2.499–15.375) were significant factors for differentiating WHO/ISUP grades.

Conclusion

Elevated TLR (> 1.63) and presence of tumor thrombus from preoperative 2-[¹⁸F]FDG PET/CT can distinguish high WHO/ISUP grade ccRCC effectively. 2-[¹⁸F]FDG PET/CT may be a feasible method for noninvasive assessment of WHO/ISUP grade.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRef

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017;71(6):918–25. https://doi.org/10.1111/his.13311.CrossRefPubMed

Moch H. The WHO/ISUP grading system for renal carcinoma. Pathologe. 2016;37(4):355–60. https://doi.org/10.1007/s00292-016-0171-y.CrossRefPubMed

Kim H, Inomoto C, Uchida T, Furuya H, Komiyama T, Kajiwara H, et al. Verification of the international society of urological pathology recommendations in Japanese patients with clear cell renal cell carcinoma. Int J Oncol. 2018;52(4):1139–48. https://doi.org/10.3892/ijo.2018.4294.CrossRefPubMedPubMedCentral

Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84. https://doi.org/10.1016/j.eururo.2011.06.021.CrossRefPubMed

Sun X, Liu L, Xu K, Li W, Huo Z, Liu H, et al. Prediction of ISUP grading of clear cell renal cell carcinoma using support vector machine model based on CT images. Medicine (Baltimore). 2019;98(14):e15022. https://doi.org/10.1097/MD.0000000000015022.CrossRef

Feng Z, Lou S, Zhang L, Zhang L, Lan W, Wang M, et al. New preoperative nomogram using the centrality index to predict high nuclear grade clear cell renal carcinoma. Cancer Manag Res. 2019;11:10921–8. https://doi.org/10.2147/cmar.S229571.CrossRefPubMedPubMedCentral

Adams LC, Jurmeister P, Ralla B, Bressem KK, Fahlenkamp UL, Engel G, et al. Assessment of the extracellular volume fraction for the grading of clear cell renal cell carcinoma: first results and histopathological findings. Eur Radiol. 2019;29(11):5832–43. https://doi.org/10.1007/s00330-019-06087-x.CrossRefPubMed

Regenet N, Sauvanet A, Muscari F, Meunier B, Mariette C, Adham M et al. The value of (18)F-FDG positron emission tomography to differentiate benign from malignant intraductal papillary mucinous neoplasms: a prospective multicenter study. J Visc Surg 2020. https://doi.org/10.1016/j.jviscsurg.2020.01.006.

10.

Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, et al. Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using (18)F-FDG PET/CT and DW-MRI: a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2020;106(5):998–1009. https://doi.org/10.1016/j.ijrobp.2019.12.038.CrossRefPubMed

11.

Noda Y, Kanematsu M, Goshima S, Suzui N, Hirose Y, Matsunaga K, et al. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas. Eur Radiol. 2015;25(10):3009–16. https://doi.org/10.1007/s00330-015-3687-2.CrossRefPubMed

12.

Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2017;27(11):4866–73. https://doi.org/10.1007/s00330-017-4875-z.CrossRefPubMed

13.

Singh H, Arora G, Nayak B, Sharma A, Singh G, Kumari K, et al. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics. Nucl Med Commun. 2020;41(5):485–93. https://doi.org/10.1097/mnm.0000000000001169.CrossRefPubMed

14.

Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–504. https://doi.org/10.1097/PAS.0b013e318299f0fb.CrossRefPubMed

15.

Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, et al. Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging. 2017;44(12):1958–68. https://doi.org/10.1007/s00259-017-3779-0.CrossRefPubMedPubMedCentral

16.

Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, et al. Renal masses detected on FDG PET/CT in patients with lymphoma: imaging features differentiating primary renal cell carcinomas from renal lymphomatous involvement. AJR Am J Roentgenol. 2017;208(4):849–53. https://doi.org/10.2214/ajr.16.17133.CrossRefPubMedPubMedCentral

17.

Ravina M, Hess S, Chauhan MS, Jacob MJ, Alavi A. Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population. Clin Nucl Med. 2014;39(9):767–71. https://doi.org/10.1097/rlu.0000000000000451.CrossRefPubMed

18.

Zhu A, Hou X, Zhang W, Zhang Y. ¹⁸F-FDG PET/CT in diagnosis of renal cell carcinoma with venous tumor thrombosis. Chin J Med Imaging Technol. 2019;35(10):1522–5. https://doi.org/10.13929/j.1003-3289.201901201.CrossRef

19.

Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–9. https://doi.org/10.1016/j.eururo.2017.12.018.CrossRefPubMed

20.

Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using ¹⁸F-FDG PET/CT. Clin Nucl Med. 2015;40(12):936–40. https://doi.org/10.1097/rlu.0000000000000875.CrossRefPubMedPubMedCentral

21.

Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr. 2007;39(3):231–4. https://doi.org/10.1007/s10863-007-9081-2.CrossRefPubMed

22.

Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–20. https://doi.org/10.2214/ajr.10.4923.CrossRefPubMed

23.

Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36(10):1836–9.PubMed

24.

Park HL, Yoo IR, Boo SH, Park SY, Park JK, Sung SW, et al. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients? J Cancer Res Clin Oncol. 2019;145(4):1021–6. https://doi.org/10.1007/s00432-019-02858-7.CrossRefPubMed

25.

Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver SUV stable over time in (1)(8)F-FDG PET imaging? J Nucl Med Technol. 2011;39(4):258–63. https://doi.org/10.2967/jnmt.111.090027.CrossRefPubMed

26.

Na SJ, o JH, Park JM, Lee HH, Lee SH, Song KY et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III gastric cancer. Oncotarget. 2016;7(39):63968–63980. https://doi.org/10.18632/oncotarget.11574

27.

Miyake H, Terakawa T, Furukawa J, Muramaki M, Fujisawa M. Prognostic significance of tumor extension into venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus. Eur J Surg Oncol. 2012;38(7):630–6. https://doi.org/10.1016/j.ejso.2012.03.006.CrossRefPubMed

28.

Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol. 2013;31(7):1305–9. https://doi.org/10.1016/j.urolonc.2011.12.006.CrossRefPubMed

29.

Sharma P, Kumar R, Jeph S, Karunanithi S, Naswa N, Gupta A, et al. ¹⁸F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun. 2011;32(9):782–8. https://doi.org/10.1097/MNM.0b013e32834774c8.CrossRefPubMed

30.

Park JW, Jo MK, Lee HM. Significance of ¹⁸F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103(5):615–9. https://doi.org/10.1111/j.1464-410X.2008.08150.x.CrossRefPubMed

31.

Wu J, Xu WH, Wei Y, Qu YY, Zhang HL, Ye DW. An integrated score and nomogram combining clinical and immunohistochemistry factors to predict high ISUP grade clear cell renal cell carcinoma. Front Oncol. 2018;8:634. https://doi.org/10.3389/fonc.2018.00634.CrossRefPubMedPubMedCentral

32.

Oh S, Sung DJ, Yang KS, Sim KC, Han NY, Park BJ, et al. Correlation of CT imaging features and tumor size with Fuhrman grade of clear cell renal cell carcinoma. Acta Radiol. 2017;58(3):376–84. https://doi.org/10.1177/0284185116649795.CrossRefPubMed

33.

Maruyama M, Yoshizako T, Uchida K, Araki H, Tamaki Y, Ishikawa N, et al. Comparison of utility of tumor size and apparent diffusion coefficient for differentiation of low- and high-grade clear-cell renal cell carcinoma. Acta Radiol. 2015;56(2):250–6. https://doi.org/10.1177/0284185114523268.CrossRefPubMed

34.

Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(3):464–73. https://doi.org/10.1007/s00259-015-3159-6.CrossRefPubMed

Titel: 2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma
verfasst von: Yanyan Zhao
Caixia Wu
Wei Li
Xueqi Chen
Ziao Li
Xuhe Liao
Yonggang Cui
Guangyu Zhao
Meng Liu
Zhanli Fu
Publikationsdatum: 19.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04996-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

2-[¹⁸F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

In vivo quantitative mapping of human mitochondrial cardiac membrane potential: a feasibility study

Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain

A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy

Histologic subtype classification of non-small cell lung cancer using PET/CT images

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma